Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) announced it will report its Q2 financial results on August 3, 2020, after market close. A conference call will occur at 1:30 PM PT to discuss the results and provide company updates. Participants can join by dialing 877-876-9173 (US) or 785-424-1667 (International) using conference ID: NBIX. The event will also be available via webcast on Neurocrine's website, with a replay accessible for about one month. The company specializes in treatments for neurological and endocrine disorders, with a diverse portfolio of FDA-approved products.

Positive

• Neurocrine anticipates potential positive financial results for Q2.
• The company has a diverse portfolio, including FDA-approved treatments for serious conditions.

Negative

• None.

SAN DIEGO, July 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, August 3, 2020. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Participants can access the live conference call by dialing 877-876-9173 (US) or 785-424-1667 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine's website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie).

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2020-financial-results-301092368.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences report its Q2 2020 financial results?

Neurocrine Biosciences will report its Q2 2020 financial results on August 3, 2020.

How can I access the Neurocrine Biosciences conference call?

You can access the conference call by dialing 877-876-9173 (US) or 785-424-1667 (International) using the conference ID: NBIX.

What time is the Neurocrine Biosciences conference call scheduled?

The conference call is scheduled for 1:30 PM Pacific Time on August 3, 2020.

Where can I find the webcast of Neurocrine Biosciences' financial results?

The webcast can be accessed on Neurocrine's website under the Investors section.